Identification

Summary

Iothalamic acid is a diagnostic contrast agent used in various medical imaging procedures, such as angiography, arthrography, and computed tomographic scans.

Brand Names
Conray, Cysto-conray, Glofil-125
Generic Name
Iothalamic acid
DrugBank Accession Number
DB09133
Background

Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 613.916
Monoisotopic: 613.76964
Chemical Formula
C11H9I3N2O4
Synonyms
  • 1-deoxy-1-(methylamino)-D-glucitol 5-acetamido-2,4,6 triiodo-N-methylisophthalamate
  • Iotalamic acid
  • Iothalamate
  • Iothalamic acid
External IDs
  • MI 216
  • MI-216
  • MI216

Pharmacology

Indication

Conray is indicated for use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography. Conray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Renal accumulation is sufficiently rapid that maximum radiographic density in the calyces and pelves occurs, in most instances, about 3 to 8 minutes after injection. In patients with impaired renal function, diagnostic opacification frequently is achieved only after prolonged periods.

Volume of distribution

Not Available

Protein binding

Iothalamate salts are poorly bound to serum albumin.

Metabolism
Not Available
Route of elimination

Following intravascular injection, Conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. The liver and small intestine provide the major alternate route of excretion. In patients with severe renal impairment, the excretion of this contrast medium through the gallbladder and into the small intestine sharply increases.

Half-life

In patients with normal renal function, the alpha and beta half-lives of Conray were approximately 10 and 90 minutes, respectively.

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Iothalamic acid which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
AcrivastineIothalamic acid may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Adefovir dipivoxilAdefovir dipivoxil may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Take on an empty stomach. Do not eat the meal that occurs before the administration of iothalamic acid for examination.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Iothalamate meglumineXUW72GOP7W13087-53-1VLHUSFYMPUDOEL-WZTVWXICSA-N
Iothalamate sodiumKDN276D83N1225-20-3WCIMWHNSWLLELS-UHFFFAOYSA-M
Iothalamate sodium I-12531J5U3Q9ZN17692-74-9Not applicable
Sodium IothalamateNot AvailableNot AvailableNot applicable
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ConrayInjection600 mg/1mLIntravascularLiebel-Flarsheim Company LLC2003-10-14Not applicableUS flag
Conray 30Solution300 mg / mLIntravascularLiebel Flarsheim Company Llc1992-01-292018-03-14Canada flag
Conray 30Injection300 mg/1mLIntravascularLiebel-Flarsheim Company LLC2012-03-262018-09-15US flag
Conray 325Solution54.3 %IntravenousTyco Healthcare1979-12-312010-01-12Canada flag
Conray 400Solution66.8 %IntravenousTyco Healthcare1964-12-312010-01-12Canada flag
Conray 400Injection668 mg/1mLIntravascularMallinckrodt1998-01-012009-12-31US flag
Conray 43Injection430 mg/1mLIntravascularLiebel-Flarsheim Company LLC2010-10-11Not applicableUS flag
Conray 43Solution430 mg / mLIntravascularLiebel Flarsheim Company Llc1980-12-312018-05-07Canada flag
Conray 60Solution600 mg / mLIntravascularLiebel Flarsheim Company Llc1951-12-31Not applicableCanada flag
Cysto Conray Inj 43%Liquid430 mg / mLUrethralMallinckrodt1973-12-312001-03-15Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
VascorayIothalamate meglumine (520 mg / mL) + Iothalamate sodium (260 mg / mL)SolutionIntra-arterial; IntravenousTyco Healthcare1986-12-182010-01-12Canada flag
VascorayIothalamate meglumine (520 mg / mL) + Iothalamate sodium (260 mg / mL)SolutionIntra-arterial; IntravenousTyco Healthcare1986-12-182010-01-12Canada flag

Categories

ATC Codes
V08AA04 — Iotalamic acid
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Acylaminobenzoic acid and derivatives
Alternative Parents
P-haloacetanilides / O-haloacetanilides / 2-halobenzoic acids / 4-halobenzoic acids / Halobenzoic acids / N-acetylarylamines / Benzoic acids / Benzamides / 1-carboxy-2-haloaromatic compounds / Benzoyl derivatives
show 11 more
Substituents
1-carboxy-2-haloaromatic compound / 2-halobenzoic acid / 2-halobenzoic acid or derivatives / 4-halobenzoic acid / 4-halobenzoic acid or derivatives / Acetamide / Acetanilide / Acylaminobenzoic acid or derivatives / Anilide / Aromatic homomonocyclic compound
show 30 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
16CHD79MIX
CAS number
2276-90-6
InChI Key
UXIGWFXRQKWHHA-UHFFFAOYSA-N
InChI
InChI=1S/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)
IUPAC Name
3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid
SMILES
CNC(=O)C1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I

References

General References
Not Available
KEGG Drug
D01258
PubChem Compound
3737
PubChem Substance
310265048
ChemSpider
3606
RxNav
1546451
ChEBI
31713
ChEMBL
CHEMBL1201300
ZINC
ZINC000003830961
Drugs.com
Drugs.com Drug Page
Wikipedia
Iotalamic_acid

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntravascular600 mg/1mL
InjectionIntravascular300 mg/1mL
SolutionIntravascular300 mg / mL
SolutionIntravenous54.3 %
InjectionIntravascular668 mg/1mL
SolutionIntravenous66.8 %
InjectionIntravascular430 mg/1mL
SolutionIntravascular430 mg / mL
SolutionIntravascular600 mg / mL
LiquidUrethral430 mg / mL
InjectionUreteral172 mg/1mL
SolutionUrethral172 mg / mL
InjectionIntravenous1 mg/1
Injection, solutionIntravenous0.275 mCi/1mL
SolutionIntra-arterial; Intravenous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.123 mg/mLALOGPS
logP2.27ALOGPS
logP2.73Chemaxon
logS-3.7ALOGPS
pKa (Strongest Acidic)2.13Chemaxon
pKa (Strongest Basic)-1.7Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area95.5 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity102.24 m3·mol-1Chemaxon
Polarizability38.58 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at September 29, 2015 22:06 / Updated at November 27, 2022 18:28